The phosphodiesterase 2A controls lymphatic junctional maturation via cGMP-dependent notch signaling

Dev Cell. 2024 Feb 5;59(3):308-325.e11. doi: 10.1016/j.devcel.2023.12.002. Epub 2023 Dec 29.

Abstract

The molecular mechanisms by which lymphatic vessels induce cell contact inhibition are not understood. Here, we identify the cGMP-dependent phosphodiesterase 2A (PDE2A) as a selective regulator of lymphatic but not of blood endothelial contact inhibition. Conditional deletion of Pde2a in mouse embryos reveals severe lymphatic dysplasia, whereas blood vessel architecture remains unaltered. In the absence of PDE2A, human lymphatic endothelial cells fail to induce mature junctions and cell cycle arrest, whereas cGMP levels, but not cAMP levels, are increased. Loss of PDE2A-mediated cGMP hydrolysis leads to the activation of p38 signaling and downregulation of NOTCH signaling. However, DLL4-induced NOTCH activation restores junctional maturation and contact inhibition in PDE2A-deficient human lymphatic endothelial cells. In postnatal mouse mesenteries, PDE2A is specifically enriched in collecting lymphatic valves, and loss of Pde2a results in the formation of abnormal valves. Our data demonstrate that PDE2A selectively finetunes a crosstalk of cGMP, p38, and NOTCH signaling during lymphatic vessel maturation.

Keywords: NOTCH signaling; PDE2A; cGMP; cell contact inhibition; claudin 5; lymphangiogenesis; lymphatic endothelial cells; p38; phosphodiesterase 2A; proliferation; vessel maturation.

MeSH terms

  • Animals
  • Cyclic Nucleotide Phosphodiesterases, Type 2* / genetics
  • Cyclic Nucleotide Phosphodiesterases, Type 2* / metabolism
  • Down-Regulation
  • Endothelial Cells / metabolism
  • Humans
  • Lymphatic Vessels* / metabolism
  • Mice
  • Signal Transduction

Substances

  • Cyclic Nucleotide Phosphodiesterases, Type 2
  • Pde2a protein, mouse
  • PDE2A protein, human